Opinion

Published within

« | ... | 1565 | 1566 | 1567 | 1568 | 1569 | 1570 | 1571 | 1572 | 1573 | ... | » »|

Type Product title / description Pub Price
ResearchWire
ResearchWire

Bath and shower products: top fragrances in new products

Published By Datamonitor
20 May 2009
ResearchWire
ResearchWire

Bath and shower products: top fragrances in new products

Published By Datamonitor
07 Jul 2010
CommentWire
CommentWire

BAT: courtroom embarrassment

BAT has been ordered to pay compensation to a cancer victim in Australia. An Australian judge threw out BAT's defense after the company destroyed internal documents relevant to the plaintiff's case. While the damages awarded may not harm BAT's huge profits, it could affect investor confidence and ultimately its share price.

Published By Datamonitor
15 Apr 2002
CommentWire
CommentWire

Bass: cashing in on UK premium beer boom

Published By Datamonitor
13 Sep 2000
CommentWire
CommentWire

Bass: beer money buys another hotel

Published By Datamonitor
22 May 2001
CommentWire
CommentWire

Basilea: promising antibiotic for MRSA

Janssen-Cilag, a subsidiary of Johnson & Johnson, has submitted a marketing authorization application to the EMEA for ceftobiprole, a new cephalosporin developed by Basilea. The drug has demonstrated potent anti-MRSA activity and in vitro activity against difficult to treat gram-negative bacteria such as multi-drug resistant Pseudomonas, potentially making it an attractive treatment option.

Published By Datamonitor
20 Jun 2007
CommentWire
CommentWire

Basilea: FDA issues approvable letter for ceftobiprole

Basilea has received an approvable letter from the FDA for its new drug, ceftobiprole. Against the backdrop of investigations into the safety of Ketek, and considering the scrutiny Telavancin has endured, the letter is yet another indication of the FDA's more rigorous and defensive approach to the drug approval process.

Published By Datamonitor
18 Mar 2008
CommentWire
CommentWire

Basilea: ceftobiprole wins first regulatory approval

Basilea Pharmaceuticals has obtained regulatory approval from Health Canada for its anti-MRSA drug, ceftobiprole. Although the Swiss biotech company is awaiting a decision from the FDA, the uptake of ceftobiprole in Canada could form the basis for more targeted sales and marketing decisions prior to launch in other markets.

Published By Datamonitor
02 Jul 2008
CommentWire
CommentWire

Basilea/J&J: MRSA drug receives European setback, J&J returns rights

The European regulator's rejection of ceftobiprole, two months after a similar response by the FDA, will delay the approval of this promising new tool to fight MRSA by about three years. The drug's regulatory setback throws up difficult strategic questions for Basilea and illustrates the challenges of developing acute care drugs.

Published By Datamonitor
23 Feb 2010
CommentWire
CommentWire

Basilea Pharmaceutica: alitretinoin could be safer alternative

Independent Swiss pharmaceutical company Basilea has announced that its dermatology drug alitretinoin has shown positive results in a second phase III clinical trial for the treatment of severe chronic hand dermatitis. Based on these results, alitretinoin could fill an important unmet need for a safer therapy in this indication.

Published By Datamonitor
27 Apr 2007

« | ... | 1565 | 1566 | 1567 | 1568 | 1569 | 1570 | 1571 | 1572 | 1573 | ... | » »|

No help is available.